Webinar – Exchange of views with AIFA on the vaccination campaign

EMA review of regdanvimab for COVID-19 to support national decisions on early use

EMA issues advice on use of REGN-COV2 antibody combination (casirivimab / imdevimab)

Adapting COVID-19 vaccines to SARS-CoV-2 variants: guidance for vaccine manufacturers

EMA starts rolling review of Celltrion antibody regdanvimab for COVID-19

EMA starts evaluating use of Veklury in COVID-19 patients not requiring supplemental oxygen

EMA receives application for conditional marketing authorisation of COVID-19 Vaccine Janssen

Clarification on Sputnik V vaccine in the EU approval process

AIFA publishes CTS opinion on monoclonal antibodies

EMA reviewing data on monoclonal antibody use for COVID-19

First AIFA Report on COVID-19 Vaccine Surveillance

EMA starts rolling review of Novavax’s COVID-19 vaccine (NVX-CoV2373)

Aifa precisa, vaccino AstraZeneca preferibile per under 55

EMA starts rolling review of REGN-COV2 antibody combination (casirivimab / imdevimab)

EMA recommends COVID-19 Vaccine AstraZeneca for authorisation in the EU

First COVID-19 vaccine safety update published

Clarification of Comirnaty dosage interval

Study on monoclonal antibodies for COVID-19: AIFA extends the terms of the call

AIFA call for a clinical study on efficacy of monoclonal antibodies for COVID-19 treatment

ICMRA statement on vaccines and regulatory processes